Recent successes in therapeutics for Ebola virus disease: no time for complacency
The PALM trial in the Democratic Republic of the Congo identified a statistically significant survival benefit for two monoclonal antibody-based therapeutics in the treatment of acute Ebola virus disease; however, substantial gaps remain in improving the outcomes of acute Ebola virus disease and for...
Gespeichert in:
| Veröffentlicht in: | The Lancet infectious diseases 2020-09, Vol.20 (9), p.e231-e237 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e237 |
|---|---|
| container_issue | 9 |
| container_start_page | e231 |
| container_title | The Lancet infectious diseases |
| container_volume | 20 |
| creator | Iversen, Patrick L Kane, Christopher D Zeng, Xiankun Panchal, Rekha G Warren, Travis K Radoshitzky, Sheli R Kuhn, Jens H Mudhasani, Rajini R Cooper, Christopher L Shurtleff, Amy C Nasar, Farooq Sunay, Melek ME Duplantier, Allen J Eaton, Brett P Zumbrun, Elizabeth E Bixler, Sandra L Martin, Shannon Meinig, J Matthew Chiang, Chih-Yuan Sanchez-Lockhart, Mariano Palacios, Gustavo F Kugelman, Jeffrey R Martins, Karen A Pitt, Margaret L Crozier, Ian Saunders, David L |
| description | The PALM trial in the Democratic Republic of the Congo identified a statistically significant survival benefit for two monoclonal antibody-based therapeutics in the treatment of acute Ebola virus disease; however, substantial gaps remain in improving the outcomes of acute Ebola virus disease and for the survivors. Ongoing efforts are needed to develop more effective strategies, particularly for individuals with severe disease, for prevention and treatment of viral persistence in immune-privileged sites, for optimisation of post-exposure prophylaxis, and to increase therapeutic breadth. As antibody-based approaches are identified and advanced, promising small-molecule antivirals currently in clinical stage development should continue to be evaluated for filovirus diseases, with consideration of their added value in combination approaches with bundled supportive care, their penetration in tissues of interest, the absence of interaction with glycoprotein-based vaccines, and filoviral breadth. |
| doi_str_mv | 10.1016/S1473-3099(20)30282-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7302789</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1473309920302826</els_id><sourcerecordid>2437381588</sourcerecordid><originalsourceid>FETCH-LOGICAL-c495t-8070ff8dcff70ece758f91300e59d01c8812d9c715b57de6837937d8658261f73</originalsourceid><addsrcrecordid>eNqFkV9vFSEQxYmxsbX6ETQkvtSHrQMsC-uDxjRVmzQx_nsmXBgsze5yC7s36beXe29t1Jc-QeA3Z2bOIeQFg1MGrHvznbVKNAL6_oTDawFc86Z7RI7qc9u0rVSPd_c9ckielnINwBSD9gk5FFx2gms4Il-_ocNppmVxDkvBQuNE5yvMdo3LHF2hIWV6vkqDpZuYl0J9LGgLvqVTonMccQe4NK4HW5Xc7TNyEOxQ8PndeUx-fjz_cfa5ufzy6eLsw2Xj2l7OjQYFIWjvQlBQZ1BSh54JAJS9B-a0Ztz3TjG5kspjp4XqhfK6k5p3LChxTN7tddfLakS_3SLbwaxzHG2-NclG8-_PFK_Mr7QxqpqldF8FTu4EcrpZsMxmjMXhMNgJ01IMb5nUQioQFX31H3qdljzV9SollNCV1JWSe8rlVErGcD8MA7MNzexCM9tEDAezC810te7l35vcV_1JqQLv9wBWPzcRsykuVq_Rx4xuNj7FB1r8BiJqpqA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2437381588</pqid></control><display><type>article</type><title>Recent successes in therapeutics for Ebola virus disease: no time for complacency</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>ProQuest Central UK/Ireland</source><creator>Iversen, Patrick L ; Kane, Christopher D ; Zeng, Xiankun ; Panchal, Rekha G ; Warren, Travis K ; Radoshitzky, Sheli R ; Kuhn, Jens H ; Mudhasani, Rajini R ; Cooper, Christopher L ; Shurtleff, Amy C ; Nasar, Farooq ; Sunay, Melek ME ; Duplantier, Allen J ; Eaton, Brett P ; Zumbrun, Elizabeth E ; Bixler, Sandra L ; Martin, Shannon ; Meinig, J Matthew ; Chiang, Chih-Yuan ; Sanchez-Lockhart, Mariano ; Palacios, Gustavo F ; Kugelman, Jeffrey R ; Martins, Karen A ; Pitt, Margaret L ; Crozier, Ian ; Saunders, David L</creator><creatorcontrib>Iversen, Patrick L ; Kane, Christopher D ; Zeng, Xiankun ; Panchal, Rekha G ; Warren, Travis K ; Radoshitzky, Sheli R ; Kuhn, Jens H ; Mudhasani, Rajini R ; Cooper, Christopher L ; Shurtleff, Amy C ; Nasar, Farooq ; Sunay, Melek ME ; Duplantier, Allen J ; Eaton, Brett P ; Zumbrun, Elizabeth E ; Bixler, Sandra L ; Martin, Shannon ; Meinig, J Matthew ; Chiang, Chih-Yuan ; Sanchez-Lockhart, Mariano ; Palacios, Gustavo F ; Kugelman, Jeffrey R ; Martins, Karen A ; Pitt, Margaret L ; Crozier, Ian ; Saunders, David L</creatorcontrib><description>The PALM trial in the Democratic Republic of the Congo identified a statistically significant survival benefit for two monoclonal antibody-based therapeutics in the treatment of acute Ebola virus disease; however, substantial gaps remain in improving the outcomes of acute Ebola virus disease and for the survivors. Ongoing efforts are needed to develop more effective strategies, particularly for individuals with severe disease, for prevention and treatment of viral persistence in immune-privileged sites, for optimisation of post-exposure prophylaxis, and to increase therapeutic breadth. As antibody-based approaches are identified and advanced, promising small-molecule antivirals currently in clinical stage development should continue to be evaluated for filovirus diseases, with consideration of their added value in combination approaches with bundled supportive care, their penetration in tissues of interest, the absence of interaction with glycoprotein-based vaccines, and filoviral breadth.</description><identifier>ISSN: 1473-3099</identifier><identifier>ISSN: 1474-4457</identifier><identifier>EISSN: 1474-4457</identifier><identifier>DOI: 10.1016/S1473-3099(20)30282-6</identifier><identifier>PMID: 32563280</identifier><language>eng</language><publisher>United States: Elsevier Ltd</publisher><subject>Antibodies, Monoclonal - therapeutic use ; Antiviral agents ; Developmental stages ; Disease ; Ebola Vaccines - immunology ; Ebola virus ; Ebolavirus ; Epidemics ; Fatalities ; Glycoproteins ; Health services ; Hemorrhagic Fever, Ebola - prevention & control ; Hemorrhagic Fever, Ebola - therapy ; Humans ; Immune privilege ; Infectious diseases ; Monoclonal antibodies ; Needlestick injuries ; Optimization ; Patients ; Post-Exposure Prophylaxis ; Prophylaxis ; RNA polymerase ; Statistical analysis ; Vaccines ; Viral diseases</subject><ispartof>The Lancet infectious diseases, 2020-09, Vol.20 (9), p.e231-e237</ispartof><rights>2020 Elsevier Ltd</rights><rights>Copyright © 2020 Elsevier Ltd. All rights reserved.</rights><rights>2020. Elsevier Ltd</rights><rights>2020 Elsevier Ltd. All rights reserved. 2020 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c495t-8070ff8dcff70ece758f91300e59d01c8812d9c715b57de6837937d8658261f73</citedby><cites>FETCH-LOGICAL-c495t-8070ff8dcff70ece758f91300e59d01c8812d9c715b57de6837937d8658261f73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2437381588?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32563280$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Iversen, Patrick L</creatorcontrib><creatorcontrib>Kane, Christopher D</creatorcontrib><creatorcontrib>Zeng, Xiankun</creatorcontrib><creatorcontrib>Panchal, Rekha G</creatorcontrib><creatorcontrib>Warren, Travis K</creatorcontrib><creatorcontrib>Radoshitzky, Sheli R</creatorcontrib><creatorcontrib>Kuhn, Jens H</creatorcontrib><creatorcontrib>Mudhasani, Rajini R</creatorcontrib><creatorcontrib>Cooper, Christopher L</creatorcontrib><creatorcontrib>Shurtleff, Amy C</creatorcontrib><creatorcontrib>Nasar, Farooq</creatorcontrib><creatorcontrib>Sunay, Melek ME</creatorcontrib><creatorcontrib>Duplantier, Allen J</creatorcontrib><creatorcontrib>Eaton, Brett P</creatorcontrib><creatorcontrib>Zumbrun, Elizabeth E</creatorcontrib><creatorcontrib>Bixler, Sandra L</creatorcontrib><creatorcontrib>Martin, Shannon</creatorcontrib><creatorcontrib>Meinig, J Matthew</creatorcontrib><creatorcontrib>Chiang, Chih-Yuan</creatorcontrib><creatorcontrib>Sanchez-Lockhart, Mariano</creatorcontrib><creatorcontrib>Palacios, Gustavo F</creatorcontrib><creatorcontrib>Kugelman, Jeffrey R</creatorcontrib><creatorcontrib>Martins, Karen A</creatorcontrib><creatorcontrib>Pitt, Margaret L</creatorcontrib><creatorcontrib>Crozier, Ian</creatorcontrib><creatorcontrib>Saunders, David L</creatorcontrib><title>Recent successes in therapeutics for Ebola virus disease: no time for complacency</title><title>The Lancet infectious diseases</title><addtitle>Lancet Infect Dis</addtitle><description>The PALM trial in the Democratic Republic of the Congo identified a statistically significant survival benefit for two monoclonal antibody-based therapeutics in the treatment of acute Ebola virus disease; however, substantial gaps remain in improving the outcomes of acute Ebola virus disease and for the survivors. Ongoing efforts are needed to develop more effective strategies, particularly for individuals with severe disease, for prevention and treatment of viral persistence in immune-privileged sites, for optimisation of post-exposure prophylaxis, and to increase therapeutic breadth. As antibody-based approaches are identified and advanced, promising small-molecule antivirals currently in clinical stage development should continue to be evaluated for filovirus diseases, with consideration of their added value in combination approaches with bundled supportive care, their penetration in tissues of interest, the absence of interaction with glycoprotein-based vaccines, and filoviral breadth.</description><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antiviral agents</subject><subject>Developmental stages</subject><subject>Disease</subject><subject>Ebola Vaccines - immunology</subject><subject>Ebola virus</subject><subject>Ebolavirus</subject><subject>Epidemics</subject><subject>Fatalities</subject><subject>Glycoproteins</subject><subject>Health services</subject><subject>Hemorrhagic Fever, Ebola - prevention & control</subject><subject>Hemorrhagic Fever, Ebola - therapy</subject><subject>Humans</subject><subject>Immune privilege</subject><subject>Infectious diseases</subject><subject>Monoclonal antibodies</subject><subject>Needlestick injuries</subject><subject>Optimization</subject><subject>Patients</subject><subject>Post-Exposure Prophylaxis</subject><subject>Prophylaxis</subject><subject>RNA polymerase</subject><subject>Statistical analysis</subject><subject>Vaccines</subject><subject>Viral diseases</subject><issn>1473-3099</issn><issn>1474-4457</issn><issn>1474-4457</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkV9vFSEQxYmxsbX6ETQkvtSHrQMsC-uDxjRVmzQx_nsmXBgsze5yC7s36beXe29t1Jc-QeA3Z2bOIeQFg1MGrHvznbVKNAL6_oTDawFc86Z7RI7qc9u0rVSPd_c9ckielnINwBSD9gk5FFx2gms4Il-_ocNppmVxDkvBQuNE5yvMdo3LHF2hIWV6vkqDpZuYl0J9LGgLvqVTonMccQe4NK4HW5Xc7TNyEOxQ8PndeUx-fjz_cfa5ufzy6eLsw2Xj2l7OjQYFIWjvQlBQZ1BSh54JAJS9B-a0Ztz3TjG5kspjp4XqhfK6k5p3LChxTN7tddfLakS_3SLbwaxzHG2-NclG8-_PFK_Mr7QxqpqldF8FTu4EcrpZsMxmjMXhMNgJ01IMb5nUQioQFX31H3qdljzV9SollNCV1JWSe8rlVErGcD8MA7MNzexCM9tEDAezC810te7l35vcV_1JqQLv9wBWPzcRsykuVq_Rx4xuNj7FB1r8BiJqpqA</recordid><startdate>20200901</startdate><enddate>20200901</enddate><creator>Iversen, Patrick L</creator><creator>Kane, Christopher D</creator><creator>Zeng, Xiankun</creator><creator>Panchal, Rekha G</creator><creator>Warren, Travis K</creator><creator>Radoshitzky, Sheli R</creator><creator>Kuhn, Jens H</creator><creator>Mudhasani, Rajini R</creator><creator>Cooper, Christopher L</creator><creator>Shurtleff, Amy C</creator><creator>Nasar, Farooq</creator><creator>Sunay, Melek ME</creator><creator>Duplantier, Allen J</creator><creator>Eaton, Brett P</creator><creator>Zumbrun, Elizabeth E</creator><creator>Bixler, Sandra L</creator><creator>Martin, Shannon</creator><creator>Meinig, J Matthew</creator><creator>Chiang, Chih-Yuan</creator><creator>Sanchez-Lockhart, Mariano</creator><creator>Palacios, Gustavo F</creator><creator>Kugelman, Jeffrey R</creator><creator>Martins, Karen A</creator><creator>Pitt, Margaret L</creator><creator>Crozier, Ian</creator><creator>Saunders, David L</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200901</creationdate><title>Recent successes in therapeutics for Ebola virus disease: no time for complacency</title><author>Iversen, Patrick L ; Kane, Christopher D ; Zeng, Xiankun ; Panchal, Rekha G ; Warren, Travis K ; Radoshitzky, Sheli R ; Kuhn, Jens H ; Mudhasani, Rajini R ; Cooper, Christopher L ; Shurtleff, Amy C ; Nasar, Farooq ; Sunay, Melek ME ; Duplantier, Allen J ; Eaton, Brett P ; Zumbrun, Elizabeth E ; Bixler, Sandra L ; Martin, Shannon ; Meinig, J Matthew ; Chiang, Chih-Yuan ; Sanchez-Lockhart, Mariano ; Palacios, Gustavo F ; Kugelman, Jeffrey R ; Martins, Karen A ; Pitt, Margaret L ; Crozier, Ian ; Saunders, David L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c495t-8070ff8dcff70ece758f91300e59d01c8812d9c715b57de6837937d8658261f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antiviral agents</topic><topic>Developmental stages</topic><topic>Disease</topic><topic>Ebola Vaccines - immunology</topic><topic>Ebola virus</topic><topic>Ebolavirus</topic><topic>Epidemics</topic><topic>Fatalities</topic><topic>Glycoproteins</topic><topic>Health services</topic><topic>Hemorrhagic Fever, Ebola - prevention & control</topic><topic>Hemorrhagic Fever, Ebola - therapy</topic><topic>Humans</topic><topic>Immune privilege</topic><topic>Infectious diseases</topic><topic>Monoclonal antibodies</topic><topic>Needlestick injuries</topic><topic>Optimization</topic><topic>Patients</topic><topic>Post-Exposure Prophylaxis</topic><topic>Prophylaxis</topic><topic>RNA polymerase</topic><topic>Statistical analysis</topic><topic>Vaccines</topic><topic>Viral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Iversen, Patrick L</creatorcontrib><creatorcontrib>Kane, Christopher D</creatorcontrib><creatorcontrib>Zeng, Xiankun</creatorcontrib><creatorcontrib>Panchal, Rekha G</creatorcontrib><creatorcontrib>Warren, Travis K</creatorcontrib><creatorcontrib>Radoshitzky, Sheli R</creatorcontrib><creatorcontrib>Kuhn, Jens H</creatorcontrib><creatorcontrib>Mudhasani, Rajini R</creatorcontrib><creatorcontrib>Cooper, Christopher L</creatorcontrib><creatorcontrib>Shurtleff, Amy C</creatorcontrib><creatorcontrib>Nasar, Farooq</creatorcontrib><creatorcontrib>Sunay, Melek ME</creatorcontrib><creatorcontrib>Duplantier, Allen J</creatorcontrib><creatorcontrib>Eaton, Brett P</creatorcontrib><creatorcontrib>Zumbrun, Elizabeth E</creatorcontrib><creatorcontrib>Bixler, Sandra L</creatorcontrib><creatorcontrib>Martin, Shannon</creatorcontrib><creatorcontrib>Meinig, J Matthew</creatorcontrib><creatorcontrib>Chiang, Chih-Yuan</creatorcontrib><creatorcontrib>Sanchez-Lockhart, Mariano</creatorcontrib><creatorcontrib>Palacios, Gustavo F</creatorcontrib><creatorcontrib>Kugelman, Jeffrey R</creatorcontrib><creatorcontrib>Martins, Karen A</creatorcontrib><creatorcontrib>Pitt, Margaret L</creatorcontrib><creatorcontrib>Crozier, Ian</creatorcontrib><creatorcontrib>Saunders, David L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Lancet infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Iversen, Patrick L</au><au>Kane, Christopher D</au><au>Zeng, Xiankun</au><au>Panchal, Rekha G</au><au>Warren, Travis K</au><au>Radoshitzky, Sheli R</au><au>Kuhn, Jens H</au><au>Mudhasani, Rajini R</au><au>Cooper, Christopher L</au><au>Shurtleff, Amy C</au><au>Nasar, Farooq</au><au>Sunay, Melek ME</au><au>Duplantier, Allen J</au><au>Eaton, Brett P</au><au>Zumbrun, Elizabeth E</au><au>Bixler, Sandra L</au><au>Martin, Shannon</au><au>Meinig, J Matthew</au><au>Chiang, Chih-Yuan</au><au>Sanchez-Lockhart, Mariano</au><au>Palacios, Gustavo F</au><au>Kugelman, Jeffrey R</au><au>Martins, Karen A</au><au>Pitt, Margaret L</au><au>Crozier, Ian</au><au>Saunders, David L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recent successes in therapeutics for Ebola virus disease: no time for complacency</atitle><jtitle>The Lancet infectious diseases</jtitle><addtitle>Lancet Infect Dis</addtitle><date>2020-09-01</date><risdate>2020</risdate><volume>20</volume><issue>9</issue><spage>e231</spage><epage>e237</epage><pages>e231-e237</pages><issn>1473-3099</issn><issn>1474-4457</issn><eissn>1474-4457</eissn><abstract>The PALM trial in the Democratic Republic of the Congo identified a statistically significant survival benefit for two monoclonal antibody-based therapeutics in the treatment of acute Ebola virus disease; however, substantial gaps remain in improving the outcomes of acute Ebola virus disease and for the survivors. Ongoing efforts are needed to develop more effective strategies, particularly for individuals with severe disease, for prevention and treatment of viral persistence in immune-privileged sites, for optimisation of post-exposure prophylaxis, and to increase therapeutic breadth. As antibody-based approaches are identified and advanced, promising small-molecule antivirals currently in clinical stage development should continue to be evaluated for filovirus diseases, with consideration of their added value in combination approaches with bundled supportive care, their penetration in tissues of interest, the absence of interaction with glycoprotein-based vaccines, and filoviral breadth.</abstract><cop>United States</cop><pub>Elsevier Ltd</pub><pmid>32563280</pmid><doi>10.1016/S1473-3099(20)30282-6</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1473-3099 |
| ispartof | The Lancet infectious diseases, 2020-09, Vol.20 (9), p.e231-e237 |
| issn | 1473-3099 1474-4457 1474-4457 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7302789 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; ProQuest Central UK/Ireland |
| subjects | Antibodies, Monoclonal - therapeutic use Antiviral agents Developmental stages Disease Ebola Vaccines - immunology Ebola virus Ebolavirus Epidemics Fatalities Glycoproteins Health services Hemorrhagic Fever, Ebola - prevention & control Hemorrhagic Fever, Ebola - therapy Humans Immune privilege Infectious diseases Monoclonal antibodies Needlestick injuries Optimization Patients Post-Exposure Prophylaxis Prophylaxis RNA polymerase Statistical analysis Vaccines Viral diseases |
| title | Recent successes in therapeutics for Ebola virus disease: no time for complacency |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T10%3A37%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recent%20successes%20in%20therapeutics%20for%20Ebola%20virus%20disease:%20no%20time%20for%20complacency&rft.jtitle=The%20Lancet%20infectious%20diseases&rft.au=Iversen,%20Patrick%20L&rft.date=2020-09-01&rft.volume=20&rft.issue=9&rft.spage=e231&rft.epage=e237&rft.pages=e231-e237&rft.issn=1473-3099&rft.eissn=1474-4457&rft_id=info:doi/10.1016/S1473-3099(20)30282-6&rft_dat=%3Cproquest_pubme%3E2437381588%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2437381588&rft_id=info:pmid/32563280&rft_els_id=S1473309920302826&rfr_iscdi=true |